Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Oct 3;29(34):4548–4554. doi: 10.1200/JCO.2011.36.5742

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2011 by American Society of Clinical Oncology

PMC Copyright notice

Fig 1. — (A) Median overall survival in patients receiving 125 mg/m² of albumin-bound (nab) paclitaxel followed by 1,000 mg/m² of gemcitabine. (B) Median overall survival correlated with a complete metabolic response compared with baseline, defined according to the European Organisation for Research and Treatment of Cancer criteria by the absence of [¹⁸F]fluorodeoxyglucose uptake (cohorts 1 and 2). (C) Median survival correlated with secreted protein acidic and rich in cysteine (SPARC; all cohorts). (D) Maximum percentage change in CA19-9 levels in patients receiving 125 mg/m² of nab-paclitaxel followed by 1,000 mg/m² of gemcitabine. PR, partial response; SD, stable disease.